Treatment of Burkitt lymphoma in adults

References

• Burkitt D. A sarcoma involving the jaws in African children. Br. J. Surg. 46, 218–223 (1958).
   PubMed Web of Science ®Google Scholar
• Burkitt D, O’Conor GT. Malignant lymphoma in African children. I. A clinical syndrome. Cancer 14, 258–269 (1961).
   PubMed Web of Science ®Google Scholar
• Ziegler JL, Morrow RH Jr, Fass L, Kyalwazi SK, Carbone PP. Treatment of Burkitt’s lymphoma with cyclophosphamide. Bibl. Haematol. 701–705 (1970).
   Google Scholar
• Nkrumah FK, Perkins IV. Burkitt’s lymphoma: a clinical study of 110 patients. Cancer 37, 671–676 (1976).
   PubMed Web of Science ®Google Scholar
• Harris NL, Jaffe ES, Stein H et al. A revised European–American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84, 1361–1392 (1994).
   PubMed Web of Science ®Google Scholar
• Magrath IT, Shiramizu B. Biology and treatment of small non-cleaved cell lymphoma. Oncology 3, 41–60 (1989).
   PubMedGoogle Scholar
• Hecht JL, Aster JC. Molecular biology of Burkitt’s lymphoma. J. Clin. Oncol. 18, 3707–3721 (2000).
   PubMed Web of Science ®Google Scholar
• Kanda K, Hu HM, Zhang L, Grandchamps J, Boxer LM. NF-κB activity is required for the deregulation of c-myc expression by the immunoglobulin heavy chain enhancer. J. Biol. Chem. 275, 32338–32346 (2000).
   PubMed Web of Science ®Google Scholar
• Harris NL, Jaffe ES, Diebold J et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November 1997. Ann. Oncol. 10, 1419–1432 (1999).
   PubMed Web of Science ®Google Scholar
• Blum KA, Lozanski G, Byrd JC. Adult Burkitt leukemia and lymphoma. Blood 104, 3009–3020 (2004).
   PubMed Web of Science ®Google Scholar
• Kemeny MM, Magrath IT, Brennan MF. The role of surgery in the management of American Burkitt’s lymphoma and its treatment. Ann. Surg. 196, 82–86 (1982).
   PubMed Web of Science ®Google Scholar
• Janus C, Edwards BK, Sariban E, Magrath IT. Surgical resection and limited chemotherapy for abdominal undifferentiated lymphomas. Cancer Treat. Rep. 68, 599–605 (1984).
   PubMedGoogle Scholar
• Frappaz D, Miron I, Brunat-Mentigny M et al. Is there still a place for initial surgery in advanced Burkitt’s lymphomas (BL)? Proc. Am. Soc. Clin. Oncol. (1995) (Abstract 1295).
   Google Scholar
• Nkrumah FK, Perkins IV, Biggar RJ. Combination chemotherapy in abdominal Burkitt’s lymphoma. Cancer 40, 1410–1416 (1977).
   PubMed Web of Science ®Google Scholar
• Rizzieri DA, Johnson JL, Niedzwiecki D et al. Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251. Cancer 100, 1438–1448 (2004).
   PubMed Web of Science ®Google Scholar
• Murphy SB, Hustu HO. A randomized trial of combined modality therapy of childhood non-Hodgkin’s lymphoma. Cancer 45, 630–637 (1980).
   PubMed Web of Science ®Google Scholar
• Patte C, Philip T, Rodary C et al. Improved survival rate in children with stage III and IV B-cell non-Hodgkin’s lymphoma and leukemia using multi-agent chemotherapy: results of a study of 114 children from the French Pediatric Oncology Society. J. Clin. Oncol. 4, 1219–1226 (1986).
   PubMed Web of Science ®Google Scholar
• Magrath IT, Janus C, Edwards BK et al. An effective therapy for both undifferentiated (including Burkitt’s) lymphomas and lymphoblastic lymphomas in children and young adults. Blood 63, 1102–1111 (1984).
   PubMed Web of Science ®Google Scholar
• Murphy SB, Bowman WP, Abromowitch M et al. Results of treatment of advanced-stage Burkitt’s lymphoma and B-cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and co-ordinated high-dose methotrexate and cytarabine. J. Clin. Oncol. 4, 1732–1739 (1986).
   PubMed Web of Science ®Google Scholar
• Bernstein JI, Coleman CN, Strickler JG, Dorfman RF, Rosenberg SA. Combined modality therapy for adults with small noncleaved cell lymphoma (Burkitt’s and non-Burkitt’s types). J. Clin. Oncol. 4, 847–858 (1986).
   PubMed Web of Science ®Google Scholar
• McMaster ML, Greer JP, Greco FA, Johnson DH, Wolff SN, Hainsworth JD. Effective treatment of small-noncleaved-cell lymphoma with high-intensity, brief-duration chemotherapy. J. Clin. Oncol. 9, 941–946 (1991).
   PubMed Web of Science ®Google Scholar
• Philip T, Meckenstock R, Deconnick E et al. Treatment of poor prognosis Burkitt’s lymphoma in adults with the Societe Francaise d’Oncologie Pediatrique LMB Protocol – a study of the Federation Nationale des Centres de Lutte Contre le Cancer (FNLCC). Eur. J. Cancer. 1954–1959 (1992) (Abstract 28).
   Google Scholar
• Soussain C, Patte C, Ostronoff M et al. Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols. Blood 85, 664–674 (1995).
   PubMed Web of Science ®Google Scholar
• Thomas DA, Cortes J, O’Brien S et al. Hyper-CVAD program in Burkitt’s-type adult acute lymphoblastic leukemia. J. Clin. Oncol. 17, 2461–2470 (1999).
   PubMed Web of Science ®Google Scholar
• Thomas DA, Cortes J, Faderl S et al. Hyper-CVAD and rituximab therapy in HIV-negative Burkitt (BL) or Burkitt-like (BLL) leukemia/lymphoma and mature B-cell acute lymphocytic leukemia (B-ALL). Proc. Am. Soc. Clin. Oncol. (2005) (Abstract 6531).
   Google Scholar
• Jost LM, Jacky E, Dommann-Scherrer C et al. Short-term weekly chemotherapy followed by high-dose therapy with autologous bone marrow transplantation for lymphoblastic and Burkitt’s lymphomas in adult patients. Ann. Oncol. 6, 445–451 (1995).
   PubMed Web of Science ®Google Scholar
• Nademanee A, Molina A, O’Donnell MR et al. Results of high-dose therapy and autologous bone marrow/stem cell transplantation during remission in poor-risk intermediate- and high-grade lymphoma: international index high and high-intermediate risk group. Blood 90, 3844–3852 (1997).
   PubMed Web of Science ®Google Scholar
• Magrath I, Adde M, Shad A et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J. Clin. Oncol. 14, 925–934 (1996).
   PubMed Web of Science ®Google Scholar
• Mead GM, Sydes MR, Walewski J et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt’s lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann. Oncol. 13, 1264–1274 (2002).
   PubMed Web of Science ®Google Scholar
• Lacasce A, Howard O, Lib S et al. Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity. Leuk. Lymphoma 45, 761–767 (2004).
   PubMed Web of Science ®Google Scholar
• Wang ES, Straus DJ, Teruya-Feldstein J et al. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. Cancer 98, 1196–1205 (2003).
   PubMed Web of Science ®Google Scholar
• Appelbaum FR, Deisseroth AB, Graw RG Jr et al. Prolonged complete remission following high dose chemotherapy of Burkitt’s lymphoma in relapse. Cancer 41, 1059–1063 (1978).
   PubMed Web of Science ®Google Scholar
• Philip T, Biron P, Philip I et al. Massive therapy and autologous bone marrow transplantation in pediatric and young adults Burkitt’s lymphoma (30 courses on 28 patients: a 5-year experience). Eur. J. Cancer Clin. Oncol. 22, 1015–1027 (1986).
   PubMedGoogle Scholar
• Sweetenham JW, Pearce R, Taghipour G, Blaise D, Gisselbrecht C, Goldstone AH. Adult Burkitt’s and Burkitt-like non-Hodgkin’s lymphoma-outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantation. J. Clin. Oncol. 14, 2465–2472 (1996).
   PubMed Web of Science ®Google Scholar
• Levine AM, Wernz JC, Kaplan L et al. Low-dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS-related lymphoma. A prospective multi-institutional trial. JAMA 266, 84–88 (1991).
   PubMed Web of Science ®Google Scholar
• Kaplan LD, Straus DJ, Testa MA et al. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin’s lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N. Engl. J. Med. 336, 1641–1648 (1997).
   PubMed Web of Science ®Google Scholar
• Straus DJ, Huang J, Testa MA, Levine AM, Kaplan LD. Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin’s lymphoma: analysis of AIDS Clinical Trials Group protocol 142-low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor. National Institute of Allergy and Infectious Diseases. J. Clin. Oncol. 16, 3601–3606 (1998).
   PubMed Web of Science ®Google Scholar
• Knowles DM, Chamulak GA, Subar M et al. Lymphoid neoplasia associated with the acquired immunodeficiency syndrome (AIDS). The New York University Medical Center experience with 105 patients (1981–1986). Ann. Intern. Med. 108, 744–753 (1988).
   PubMed Web of Science ®Google Scholar
• Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Out-patient Study Investigators. N. Engl. J. Med. 338, 853–860 (1998).
   PubMed Web of Science ®Google Scholar
• Lim ST, Karim R, Nathwani BN, Tulpule A, Espina B, Levine AM. AIDS-related Burkitt’s lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J. Clin. Oncol. 23, 4430–4438 (2005).
   PubMed Web of Science ®Google Scholar
• Davi F, Delecluse HJ, Guiet P et al. Burkitt-like lymphomas in AIDS patients: characterization within a series of 103 human immunodeficiency virus-associated non-Hodgkin’s lymphomas. Burkitt’s Lymphoma Study Group. J. Clin. Oncol. 16, 3788–3795 (1998).
   PubMed Web of Science ®Google Scholar
• Lichtman SM, Calderon N. Alternating CODOX-M and IVAC in HIV positive patients with Burkitt’s lymphoma. Proc. Am. Soc. Clin. Oncol. 22, 614 (2003).
   Google Scholar
• Horst HA, Faetkenheuer G, Wyen C et al. AIDS-associated Burkitt- or Burkitt-like lymphoma – the short-term, multiagent and dose intensive B-ALL protocol is feasible and effective. Blood 102 (2003) (Abstract 1001).
   Google Scholar
• Cohen LF, Balow JE, Magrath IT, Poplack DG, Ziegler JL. Acute tumor lysis syndrome. A review of 37 patients with Burkitt’s lymphoma. Am. J. Med. 68, 486–491 (1980).
   PubMed Web of Science ®Google Scholar
• Frei E III, Bentzel CJ, Rieselbach R, Block JB. Renal complications of neoplastic disease. J. Chronic Dis. 16, 757–776 (1963).
   Google Scholar
• Wechsler DS, Kastan MB, Fivush BA. Resolution of nephrocalcinosis associated with tumor lysis syndrome. Pediatr. Hematol. Oncol. 11, 115–118 (1994).
   PubMed Web of Science ®Google Scholar
• Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br. J. Haematol. 127, 3–11 (2004).
   PubMed Web of Science ®Google Scholar
• Jones DP, Mahmoud H, Chesney RW. Tumor lysis syndrome: pathogenesis and management. Pediatr. Nephrol. 9, 206–212 (1995).
   Google Scholar
• Krakoff IH, Meyer RL. Prevention of hyperuricemia in leukemia and lymphoma: use of alopurinol, a xanthine oxidase inhibitor. JAMA 193, 1–6 (1965).
   PubMed Web of Science ®Google Scholar
• Spector T. Inhibition of urate production by allopurinol. Biochem. Pharmacol. 26, 355–358 (1977).
   Google Scholar
• Pui CH. Rasburicase: a potent uricolytic agent. Expert Opin. Pharmacother.3, 433–442 (2002).
   PubMedGoogle Scholar
• Band PR, Silverberg DS, Henderson JF et al. Xanthine nephropathy in a patient with lymphosarcoma treated with allopurinol. N. Engl. J. Med. 283, 354–357 (1970).
   PubMed Web of Science ®Google Scholar
• Landgrebe AR, Nyhan WL, Coleman M. Urinary-tract stones resulting from the excretion of oxypurinol. N. Engl. J. Med.292, 626–627 (1975).
   PubMed Web of Science ®Google Scholar
• Yeldandi AV, Yeldandi V, Kumar S et al. Molecular evolution of the urate oxidase-encoding gene in hominoid primates: nonsense mutations. Gene 109, 281–284 (1991).
   PubMed Web of Science ®Google Scholar
• Pui CH, Relling MV, Lascombes F et al. Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia 11, 1813–1816 (1997).
   Google Scholar
• Mahmoud HH, Leverger G, Patte C, Harvey E, Lascombes F. Advances in the management of malignancy-associated hyperuricaemia. Br. J. Cancer 77(Suppl. 4), 18–20 (1998).
   Google Scholar
• Pui CH, Mahmoud HH, Wiley JM et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J. Clin. Oncol.19, 697–704 (2001).
   PubMed Web of Science ®Google Scholar
• Goldman SC, Holcenberg JS, Finklestein JZ. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 97, 2998–3003 (2001).
   PubMed Web of Science ®Google Scholar
• Cheson BD, Dutcher BS. Managing malignancy-associated hyperuricemia with rasburicase. J. Support Oncol.3, 117–124 (2005).
   PubMedGoogle Scholar
• Hummel M, Buchheidt D, Reiter S, Bergmann J, Hofheinz R, Hehlmann R. Successful treatment of hyperuricemia with low doses of recombinant urate oxidase in four patients with hematologic malignancy and tumor lysis syndrome. Leukemia 17, 2542–2544 (2003).
   PubMed Web of Science ®Google Scholar
• Lee AC, Li CH, So KT, Chan R. Treatment of impending tumor lysis with single-dose rasburicase. Ann. Pharmacother. 37, 1614–1617 (2003).
   PubMed Web of Science ®Google Scholar
• Liu CY, Sims-McCallum RP, Schiffer CA. A single dose of rasburicase is sufficient for the treatment of hyperuricemia in patients receiving chemotherapy. Leuk. Res. 29, 463–465 (2005).
   PubMed Web of Science ®Google Scholar
• Cruz JM, Chauvenet AR. Optimizing care with rasburicase. J. Support Oncol. 3, 127–128 (2005).
   Google Scholar